Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2020 Aug;24(40):1–190. doi: 10.3310/hta24400

Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.

Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn
PMCID: PMC7505360  PMID: 32880572

Abstract

BACKGROUND

The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes for people with human epidermal growth factor receptor 2 (HER2)-positive, early, potentially curable breast cancer. Twelve months' trastuzumab, tested in registration trials, was adopted as standard adjuvant treatment in 2006. Subsequently, similar outcomes were demonstrated using 9 weeks of trastuzumab. Shorter durations were therefore tested for non-inferiority.

OBJECTIVES

To establish whether or not 6 months' adjuvant trastuzumab is non-inferior to 12 months' in the treatment of HER2-positive early breast cancer using a primary end point of 4-year disease-free survival.

DESIGN

This was a Phase III randomised controlled non-inferiority trial.

SETTING

The setting was 152 NHS hospitals.

PARTICIPANTS

A total of 4088 patients with HER2-positive early breast cancer who it was planned would receive both chemotherapy and trastuzumab took part.

INTERVENTION

Randomisation (1 : 1) to 6 months' or 12 months' trastuzumab treatment.

MAIN OUTCOMES

The primary end point was disease-free survival. The secondary end points were overall survival, cost-effectiveness and cardiac function during treatment with trastuzumab. Assuming a 4-year disease-free survival rate of 80% with 12 months' trastuzumab, 4000 patients were required to demonstrate non-inferiority of 6 months' trastuzumab (5% one-sided significance, 85% power), defining the non-inferiority limit as no worse than 3% below the standard arm. Costs and quality-adjusted life-years were estimated using a within-trial analysis and a lifetime decision-analytic model.

RESULTS

Between 4 October 2007 and 31 July 2015, 2045 patients were randomised to 12 months' trastuzumab and 2043 were randomised to 6 months' trastuzumab. Sixty-nine per cent of patients had ER-positive disease; 90% received anthracyclines (49% with taxanes; 41% without taxanes); 10% received taxanes without anthracyclines; 54% received trastuzumab sequentially after chemotherapy; and 85% received adjuvant chemotherapy (58% were node negative). At 6.1 years' median follow-up, with 389 (10%) deaths and 566 (14%) disease-free survival events, the 4-year disease-free survival rates for the 4088 patients were 89.5% (95% confidence interval 88.1% to 90.8%) in the 6-month group and 90.3% (95% confidence interval 88.9% to 91.5%) in the 12-month group (hazard ratio 1.10, 90% confidence interval 0.96 to 1.26; non-inferiority p = 0.01), demonstrating non-inferiority of 6 months' trastuzumab. Congruent results were found for overall survival (non-inferiority p = 0.0003) and landmark analyses 6 months from starting trastuzumab [non-inferiority p = 0.03 (disease-free-survival) and p = 0.006 (overall survival)]. Six months' trastuzumab resulted in fewer patients reporting adverse events of severe grade [365/1929 (19%) vs. 460/1935 (24%) for 12-month patients; p = 0.0003] or stopping early because of cardiotoxicity [61/1977 (3%) vs. 146/1941 (8%) for 12-month patients; p < 0.0001]. Health economic analysis showed that 6 months' trastuzumab resulted in significantly lower lifetime costs than and similar lifetime quality-adjusted life-years to 12 months' trastuzumab, and thus there is a high probability that 6 months' trastuzumab is cost-effective compared with 12 months' trastuzumab. Patient-reported experiences in the trial highlighted fatigue and aches and pains most frequently.

LIMITATIONS

The type of chemotherapy and timing of trastuzumab changed during the recruitment phase of the study as standard practice altered.

CONCLUSIONS

PERSEPHONE demonstrated that, in the treatment of HER2-positive early breast cancer, 6 months' adjuvant trastuzumab is non-inferior to 12 months'. Six months' treatment resulted in significantly less cardiac toxicity and fewer severe adverse events.

FUTURE WORK

Ongoing translational work investigates patient and tumour genetic determinants of toxicity, and trastuzumab efficacy. An individual patient data meta-analysis with PHARE and other trastuzumab duration trials is planned.

TRIAL REGISTRATION

Current Controlled Trials ISRCTN52968807, EudraCT 2006-007018-39 and ClinicalTrials.gov NCT00712140.

FUNDING

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 40. See the NIHR Journals Library website for further project information.

Plain language summary

THE BACKGROUND

There are several different types of breast cancer and some are called ‘HER2 positive’. These cancers can often be cured by treatment with chemotherapy and a drug called trastuzumab (also known as Herceptin®; Roche, Basel, Switzerland). Although the first trials of trastuzumab used 12 months treatment, we did not know if less treatment could work as well. A small trial in Finland showed that giving trastuzumab for just 9 weeks was also effective. We know that trastuzumab can have some side effects, including heart problems, so it was important to see if we could reduce the length of treatment time, which is usually 12 months.

WHAT DID WE DO?

We wanted to find out if we could treat patients safely with 6 months rather than 12 months of trastuzumab. We carried out a clinical trial called PERSEPHONE, in which over 4000 patients with this type of early breast cancer took part. Half of the patients were given 12 months of trastuzumab and half were given 6 months of trastuzumab.

WHAT DID WE FIND?

We found that the two groups of patients had very similar benefit from treatment. At 4 years after diagnosis 90.3% of those who had received 12 months of trastuzumab were alive and free of any breast cancer recurrence, compared with 89.5% of those who had received 6 months. In other words, 125 patients would need to be treated with 12 months’ trastuzumab rather than 6 months’ trastuzumab for one more person to be alive and cancer-free 4 years from diagnosis.

THE SIDE EFFECTS?

Severe side effects of trastuzumab were seen on at least one occasion in 24% of 12-month patients compared with 19% of 6-month patients. More patients receiving 12 months of trastuzumab had to stop trastuzumab early because of heart problems (8% of 12-month patients compared with 3% of 6-month patients).

WHAT DOES THIS ALL MEAN?

We have shown that 6 months of trastuzumab has similar outcomes to 12 months in treating patients with HER2-positive early breast cancer but with fewer severe side effects, including heart problems, fewer visits to hospital for patients and significant cost savings for the NHS.

Full text of this article can be found in Bookshelf.

References

  1. Cancer Research UK. Breast Cancer Statistics. URL: www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer (accessed 3 July 2020).
  2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82. https://doi.org/10.1126/science.3798106 doi: 10.1126/science.3798106. [DOI] [PubMed]
  3. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747–52. https://doi.org/10.1038/35021093 doi: 10.1038/35021093. [DOI] [PubMed]
  4. Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015;24(Suppl. 2):26–35. https://doi.org/10.1016/j.breast.2015.07.008 doi: 10.1016/j.breast.2015.07.008. [DOI] [PubMed]
  5. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346–52. https://doi.org/10.1038/nature10983 doi: 10.1038/nature10983. [DOI] [PMC free article] [PubMed]
  6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92. https://doi.org/10.1056/NEJM200103153441101 doi: 10.1056/NEJM200103153441101. [DOI] [PubMed]
  7. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719–26. https://doi.org/10.1200/JCO.2002.20.3.719 doi: 10.1200/JCO.2002.20.3.719. [DOI] [PubMed]
  8. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D’Amico R. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012;4:CD006243. https://doi.org/10.1002/14651858.CD006243.pub2 doi: 10.1002/14651858.CD006243.pub2. [DOI] [PMC free article] [PubMed]
  9. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199–209. https://doi.org/10.1056/NEJMoa1213261 doi: 10.1056/NEJMoa1213261. [DOI] [PubMed]
  10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72. https://doi.org/10.1056/NEJMoa052306 doi: 10.1056/NEJMoa052306. [DOI] [PubMed]
  11. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29–36. https://doi.org/10.1016/S0140-6736(07)60028-2 doi: 10.1016/S0140-6736(07)60028-2. [DOI] [PubMed]
  12. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 2013;382:1021–8. https://doi.org/10.1016/S0140-6736(13)61094-6 doi: 10.1016/S0140-6736(13)61094-6. [DOI] [PubMed]
  13. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017;389:1195–205. https://doi.org/10.1016/S0140-6736(16)32616-2 doi: 10.1016/S0140-6736(16)32616-2. [DOI] [PMC free article] [PubMed]
  14. Joensuu H. Duration of adjuvant trastuzumab: shorter beats longer. Lancet 2013;382:1010–11. https://doi.org/10.1016/S0140-6736(13)61448-8 doi: 10.1016/S0140-6736(13)61448-8. [DOI] [PubMed]
  15. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–84. https://doi.org/10.1056/NEJMoa052122 doi: 10.1056/NEJMoa052122. [DOI] [PubMed]
  16. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011;29:4491–7. https://doi.org/10.1200/JCO.2011.36.7045 doi: 10.1200/JCO.2011.36.7045. [DOI] [PMC free article] [PubMed]
  17. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014;32:3744–52. https://doi.org/10.1200/JCO.2014.55.5730 doi: 10.1200/JCO.2014.55.5730. [DOI] [PMC free article] [PubMed]
  18. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273–83. https://doi.org/10.1056/NEJMoa0910383 doi: 10.1056/NEJMoa0910383. [DOI] [PMC free article] [PubMed]
  19. Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009;27:6129–34. https://doi.org/10.1200/JCO.2009.23.0946 doi: 10.1200/JCO.2009.23.0946. [DOI] [PubMed]
  20. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–20. https://doi.org/10.1056/NEJMoa053028 doi: 10.1056/NEJMoa053028. [DOI] [PubMed]
  21. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009;27:5685–92. https://doi.org/10.1200/JCO.2008.21.4577 doi: 10.1200/JCO.2008.21.4577. [DOI] [PubMed]
  22. Schneider BP, O’Neill A, Shen F, Sledge GW, Thor AD, Kahanic SP, et al. Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 2015;113:1651–7. https://doi.org/10.1038/bjc.2015.405 doi: 10.1038/bjc.2015.405. [DOI] [PMC free article] [PubMed]
  23. Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013;14:741–8. https://doi.org/10.1016/S1470-2045(13)70225-0 doi: 10.1016/S1470-2045(13)70225-0. [DOI] [PubMed]
  24. Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol 2015;26:1333–40. https://doi.org/10.1093/annonc/mdv213 doi: 10.1093/annonc/mdv213. [DOI] [PubMed]
  25. Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs. 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial. JAMA Oncol 2018;4:1199–206. https://doi.org/10.1001/jamaoncol.2018.1380 doi: 10.1001/jamaoncol.2018.1380. [DOI] [PMC free article] [PubMed]
  26. Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Ann Oncol 2018;29:2328–33. https://doi.org/10.1093/annonc/mdy414 doi: 10.1093/annonc/mdy414. [DOI] [PubMed]
  27. International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Efficacy Guidelines. URL: www.ich.org/page/efficacy-guidelines (accessed 3 July 2020).
  28. NHS Health Research Authority. Good Clinical Practice. URL: www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/good-clinical-practice/ (accessed 3 July 2020).
  29. Great Britain. The Medicines for Human Use (Clinical Trials) Regulations 2004. London: The Stationery Office; 2004.
  30. NHS Health Research Authority. Clinical Trials of Investigational Medicinal Products (CTIMPS). URL: www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/clinical-trials-investigational-medicinal-products-ctimps/ (accessed 3 July 2020).
  31. Warwick Clinical Trials Unit. Persephone Protocol v5.0 Sept 2019. URL: https://warwick.ac.uk/fac/sci/med/research/ctu/trials/cancer/persephone/professionals (accessed 3 July 2020).
  32. Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, et al. Best Practice No. 176: updated recommendations for HER2 testing in the UK. J Clin Pathol 2004;57:233–7. https://doi.org/10.1136/jcp.2003.007724 doi: 10.1136/jcp.2003.007724. [DOI] [PMC free article] [PubMed]
  33. Walker RA, Bartlett JM, Dowsett M, Ellis IO, Hanby AM, Jasani B, et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol 2008;61:818–24. https://doi.org/10.1136/jcp.2007.054866 doi: 10.1136/jcp.2007.054866. [DOI] [PubMed]
  34. Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, et al. Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol 2015;68:93–9. https://doi.org/10.1136/jclinpath-2014-202571 doi: 10.1136/jclinpath-2014-202571. [DOI] [PMC free article] [PubMed]
  35. Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, et al. HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol 2016;34:3518–28. https://doi.org/10.1200/JCO.2016.66.6693 doi: 10.1200/JCO.2016.66.6693. [DOI] [PMC free article] [PubMed]
  36. Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009;100:684–92. https://doi.org/10.1038/sj.bjc.6604909 doi: 10.1038/sj.bjc.6604909. [DOI] [PMC free article] [PubMed]
  37. Cancer Research UK. Trans-PERSEPHONE and Trans-PERSEPHONE-SNPs: The Pharmacogenomics and Pharmacogenetics of Adjuvant Trastuzumab. Cancer Research Translational research in Clinical Trials Committee Project Grant: Funding Reference Number: C507/A9675, 2008–2015. URL: https://europepmc.org/grantfinder/grantdetails?query=pi%3A%22Caldas%2BC%22%2Bgid%3A%22A18832%22%2Bga%3A%22Cancer%20Research%20UK%22
  38. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012;13:869–78. https://doi.org/10.1016/S1470-2045(12)70329-7 doi: 10.1016/S1470-2045(12)70329-7. [DOI] [PubMed]
  39. Mauri L, D’Agostino RB. Challenges in the design and interpretation of noninferiority trials. N Engl J Med 2017;377:1357–67. https://doi.org/10.1056/NEJMra1510063 doi: 10.1056/NEJMra1510063. [DOI] [PubMed]
  40. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378:1177–88. https://doi.org/10.1056/NEJMoa1713709 doi: 10.1056/NEJMoa1713709. [DOI] [PMC free article] [PubMed]
  41. Mehanna H, Wong WL, McConkey CC, Rahman JK, Robinson M, Hartley AG, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med 2016;374:1444–54. https://doi.org/10.1056/NEJMoa1514493 doi: 10.1056/NEJMoa1514493. [DOI] [PubMed]
  42. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379:111–21. https://doi.org/10.1056/NEJMoa1804710 doi: 10.1056/NEJMoa1804710. [DOI] [PMC free article] [PubMed]
  43. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191–4. https://doi.org/10.1016/S0140-6736(00)04337-3 doi: 10.1016/S0140-6736(00)04337-3. [DOI] [PubMed]
  44. Early Breast Cancer Trialists’ Collaborative Group. Treatment of Early Breast Cancer: Worldwide Evidence 1985–1990. Oxford: Oxford University Press; 1990.
  45. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC; 1999. https://doi.org/10.1201/9781584888581 doi: 10.1201/9781584888581. [DOI]
  46. Freidlin B, Korn EL, Gray R. A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials 2010;7:197–208. https://doi.org/10.1177/1740774510369019 doi: 10.1177/1740774510369019. [DOI] [PubMed]
  47. Pivot X, Romieu G, Bonnefoi H, Pierga JY, Kerbrat P, Guastalla JP, et al. PHARE trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Ann Oncol 2012;23(Suppl. 9):ixe1–ixe30. https://doi.org/10.1016/S0923-7534(20)34322-2 doi: 10.1016/S0923-7534(20)34322-2. [DOI]
  48. Goldhirsch A, Piccartt MJ, Procter M, de Azambuja E, Weber HA, Untch M, et al. HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Ann Oncol 2012;23(Suppl. 9):ixe1–ixe30. https://doi.org/10.1016/S0923-7534(20)34333-7 doi: 10.1016/S0923-7534(20)34333-7. [DOI]
  49. Independent Cancer Patients’ Voice. About Us. URL: www.independentcancerpatientsvoice.org.uk/about-us/
  50. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88. https://doi.org/10.1016/0197-2456(86)90046-2 doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed]
  51. Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 2019;393:2591–8. doi: 10.1016/S0140-6736(19)30653-1. [DOI] [PubMed]
  52. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215–21. https://doi.org/10.1200/JCO.2002.20.5.1215 doi: 10.1200/JCO.2002.20.5.1215. [DOI] [PubMed]
  53. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811–19. https://doi.org/10.1200/JCO.2005.02.4091 doi: 10.1200/JCO.2005.02.4091. [DOI] [PubMed]
  54. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007;25:3859–65. https://doi.org/10.1200/JCO.2006.09.1611 doi: 10.1200/JCO.2006.09.1611. [DOI] [PubMed]
  55. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010;28:3422–8. https://doi.org/10.1200/JCO.2009.26.0463 doi: 10.1200/JCO.2009.26.0463. [DOI] [PubMed]
  56. de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol 2014;32:2159–65. https://doi.org/10.1200/JCO.2013.53.9288 doi: 10.1200/JCO.2013.53.9288. [DOI] [PubMed]
  57. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231–8. https://doi.org/10.1200/JCO.2007.13.5467 doi: 10.1200/JCO.2007.13.5467. [DOI] [PMC free article] [PubMed]
  58. Russell SD, Blackwell KL, Lawrence J, Pippen JE, Roe MT, Wood F, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010;28:3416–21. https://doi.org/10.1200/JCO.2009.23.6950 doi: 10.1200/JCO.2009.23.6950. [DOI] [PubMed]
  59. Zeglinski M, Ludke A, Jassal DS, Singal PK. Trastuzumab-induced cardiac dysfunction: a ‘dual-hit’. Exp Clin Cardiol 2011;16:70–4. [PMC free article] [PubMed]
  60. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332–44. https://doi.org/10.1038/nrc2106 doi: 10.1038/nrc2106. [DOI] [PubMed]
  61. Ewer MS, Gibbs HR, Swafford J, Benjamin RS. Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 1999;26(Suppl. 4):96–101. [PubMed]
  62. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820–6. https://doi.org/10.1200/JCO.2005.13.300 doi: 10.1200/JCO.2005.13.300. [DOI] [PubMed]
  63. Pivot X, Suter T, Nabholtz JM, Pierga JY, Espie M, Lortholary A, et al. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. Eur J Cancer 2015;51:1660–6. https://doi.org/10.1016/j.ejca.2015.05.028 doi: 10.1016/j.ejca.2015.05.028. [DOI] [PubMed]
  64. Mantarro S, Rossi M, Bonifazi M, D’Amico R, Blandizzi C, La Vecchia C, et al. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med 2016;11:123–40. https://doi.org/10.1007/s11739-015-1362-x doi: 10.1007/s11739-015-1362-x. [DOI] [PubMed]
  65. Dolgin M, Fox AC, Levin RI, editors. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. London: Little, Brown; 1994.
  66. Raphael C, Briscoe C, Davies J, Whinnett ZI, Manisty C, Sutton R, et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart 2007;93:476–82. https://doi.org/10.1136/hrt.2006.089656 doi: 10.1136/hrt.2006.089656. [DOI] [PMC free article] [PubMed]
  67. Beauclair S, Formento P, Fischel JL, Lescaut W, Largillier R, Chamorey E, et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol 2007;18:1335–41. https://doi.org/10.1093/annonc/mdm181 doi: 10.1093/annonc/mdm181. [DOI] [PubMed]
  68. Ng T, Chan M, Khor CC, Ho HK, Chan A. The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review. Cancer Treat Rev 2014;40:1199–214. https://doi.org/10.1016/j.ctrv.2014.10.001 doi: 10.1016/j.ctrv.2014.10.001. [DOI] [PubMed]
  69. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009;27:2638–44. https://doi.org/10.1200/JCO.2008.17.9549 doi: 10.1200/JCO.2008.17.9549. [DOI] [PMC free article] [PubMed]
  70. Leong SL, Chaiyakunapruk N, Tassaneeyakul W, Arunmanakul P, Nathisuwan S, Lee SWH. Roles of pharmacogenomics in non-anthracycline antineoplastic-induced cardiovascular toxicities: a systematic review and meta-analysis of genotypes effect. Int J Cardiol 2019;280:190–7. https://doi.org/10.1016/j.ijcard.2018.12.049 doi: 10.1016/j.ijcard.2018.12.049. [DOI] [PubMed]
  71. Roca L, Diéras V, Roché H, Lappartient E, Kerbrat P, Cany L, et al. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. Breast Cancer Res Treat 2013;139:789–800. https://doi.org/10.1007/s10549-013-2587-x doi: 10.1007/s10549-013-2587-x. [DOI] [PubMed]
  72. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987–98. https://doi.org/10.1056/NEJMoa1209825 doi: 10.1056/NEJMoa1209825. [DOI] [PubMed]
  73. Earl H, Hiller L, Dunn J, Blenkinsop C, Grybowicz L, Vallier AL, et al. Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: the ARTemis trial. J Clin Oncol 2016;34(Suppl.):abstr 1014. https://doi.org/10.1200/JCO.2016.34.15_suppl.1014 doi: 10.1200/JCO.2016.34.15_suppl.1014. [DOI]
  74. Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006;355:1851–62. https://doi.org/10.1056/NEJMoa052084 doi: 10.1056/NEJMoa052084. [DOI] [PubMed]
  75. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717. https://doi.org/10.1016/S0140-6736(05)66544-0 doi: 10.1016/S0140-6736(05)66544-0. [DOI] [PubMed]
  76. Bartlett JM, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, et al. Predicting anthracycline benefit: TOP2A and CEP17-not only but also. J Clin Oncol 2015;33:1680–7. https://doi.org/10.1200/JCO.2013.54.7869 doi: 10.1200/JCO.2013.54.7869. [DOI] [PubMed]
  77. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–72. https://doi.org/10.1016/0168-8510(96)00822-6 doi: 10.1016/0168-8510(96)00822-6. [DOI] [PubMed]
  78. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013. URL: www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 (accessed 3 July 2020). [PubMed]
  79. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108. https://doi.org/10.1097/00005650-199711000-00002 doi: 10.1097/00005650-199711000-00002. [DOI] [PubMed]
  80. Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQol: Results From a UK General Population Survey. York: Centre for Health Economics, University of York; 1995.
  81. Shen LZ, Pulkstenis E, Hoseyni M. Estimation of mean quality adjusted survival time. Stat Med 1999;18:1541–54. https://doi.org/10.1002/(SICI)1097-0258(19990630)18:12<1541::AID-SIM139>3.0.CO;2-Z doi: 10.1002/(SICI)1097-0258(19990630)18:12&#x0003c;1541::AID-SIM139&#x0003e;3.0.CO;2-Z. [DOI] [PubMed]
  82. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990;300:230–5. https://doi.org/10.1136/bmj.300.6719.230 doi: 10.1136/bmj.300.6719.230. [DOI] [PMC free article] [PubMed]
  83. Lidgren M, Wilking N, Jonsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res 2007;16:1073–81. https://doi.org/10.1007/s11136-007-9202-8 doi: 10.1007/s11136-007-9202-8. [DOI] [PubMed]
  84. Hunter RM, Baio G, Butt T, Morris S, Round J, Freemantle N. An educational review of the statistical issues in analysing utility data for cost-utility analysis. PharmacoEconomics 2015;33:355–66. https://doi.org/10.1007/s40273-014-0247-6 doi: 10.1007/s40273-014-0247-6. [DOI] [PubMed]
  85. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487–96. https://doi.org/10.1002/hec.944 doi: 10.1002/hec.944. [DOI] [PubMed]
  86. Curtis L, Burns A. Unit Costs of Health and Social Care 2018. Canterbury: Personal Social Services Research Unit, University of Kent; 2018.
  87. NHS Improvement. NHS Reference Costs 2017/18. URL: https://improvement.nhs.uk/resources/reference-costs/ (accessed 3 July 2020).
  88. Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press; 2018. URL: www.medicinescomplete.com (accessed 7 July 2020).
  89. O’Brien GL, O’Mahony C, Cooke K, Kinneally A, Sinnott SJ, Walshe V, et al. Cost minimization analysis of intravenous or subcutaneous trastuzumab treatment in patients with HER2-positive breast cancer in Ireland. Clin Breast Cancer 2019;19:e440–51. https://doi.org/10.1016/j.clbc.2019.01.011 doi: 10.1016/j.clbc.2019.01.011. [DOI] [PubMed]
  90. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEconomics 2014;32:1157–70. https://doi.org/10.1007/s40273-014-0193-3 doi: 10.1007/s40273-014-0193-3. [DOI] [PMC free article] [PubMed]
  91. Hall PS, Hulme C, McCabe C, Oluboyede Y, Round J, Cameron DA. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence. PharmacoEconomics 2011;29:415–32. https://doi.org/10.2165/11588340-000000000-00000 doi: 10.2165/11588340-000000000-00000. [DOI] [PubMed]
  92. Karnon J, Kerr GR, Jack W, Papo NL, Cameron DA. Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. Br J Cancer 2007;97:479–85. https://doi.org/10.1038/sj.bjc.6603887 doi: 10.1038/sj.bjc.6603887. [DOI] [PMC free article] [PubMed]
  93. Mohan N, Jiang J, Dokmanovic M, Wu WJ. Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antib Ther 2018;1:13–17. https://doi.org/10.1093/abt/tby003 doi: 10.1093/abt/tby003. [DOI] [PMC free article] [PubMed]
  94. Townsend N, Wickramasinghe K, Bhatnagar P, Smolina K, Nichols M, Leal J, et al. Coronary Heart Disease Statistics 2012 Edition. London: British Heart Foundation; 2012.
  95. Office for National Statistics. National Life Tables: UK. URL: www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables (accessed 1 November 2019).
  96. Cancer Research UK. Breast Cancer Mortality Statistics. URL: www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/mortality?_ga=2.233072414.1882256152.1588694623-1974509419.1582545276#heading-One (accessed 1 November 2019).
  97. Jackson CH. Multi-state models for panel data: the msm package for R. Stat Software 2011;38:1–29. https://doi.org/10.18637/jss.v038.i08 doi: 10.18637/jss.v038.i08. [DOI]
  98. Seferina SC, Ramaekers BLT, de Boer M, Dercksen MW, van den Berkmortel F, van Kampen RJW, et al. Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: a study of the Southeast Netherlands Breast Cancer Consortium. Oncotarget 2017;8:79223–33. https://doi.org/10.18632/oncotarget.16985 doi: 10.18632/oncotarget.16985. [DOI] [PMC free article] [PubMed]
  99. Bank of England. Inflation Calculator. URL: www.bankofengland.co.uk/monetary-policy/inflation/inflation-calculator (accessed 3 July 2020).
  100. National Institute for Health and Care Excellence (NICE). Early and Locally Advanced Breast Cancer: Diagnosis and Management. NICE guideline [NG101]. London: NICE; 2018. URL: www.nice.org.uk/guidance/ng101 (accessed 3 July 2020). [PubMed]
  101. Robertson C, Arcot Ragupathy SK, Boachie C, Dixon JM, Fraser C, Hernández R, et al. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation. Health Technol Assess 2011;15(34). https://doi.org/10.3310/hta15340 doi: 10.3310/hta15340. [DOI] [PMC free article] [PubMed]
  102. Stein RC, Dunn JA, Bartlett JM, Campbell AF, Marshall A, Hall P, et al. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technol Assess 2016;20(10). https://doi.org/10.3310/hta20100 doi: 10.3310/hta20100. [DOI] [PMC free article] [PubMed]
  103. Hall P, Walkington L, Newsham A, Hall G, Glaser A. Costs of hospital care over ten years from diagnosis of early breast cancer in England. Eur J Cancer 2014;50:S79–80.
  104. National Institute for Health and Care Excellence (NICE). Abemaciclib with an Aromatase Inhibitor for Previously Untreated, Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer. Technology appraisal guidance [TA563]. London: NICE; 2019. URL: www.nice.org.uk/guidance/ta563 (accessed 3 July 2020).
  105. National Institute for Health and Care Excellence (NICE). Advanced Breast Cancer: Diagnosis and Treatment. Clinical guideline [CG81]. London: NICE; 2017. URL: www.nice.org.uk/guidance/cg81 (accessed 3 July 2020).
  106. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. PharmacoEconomics 1996;9:113–20. https://doi.org/10.2165/00019053-199609020-00003 doi: 10.2165/00019053-199609020-00003. [DOI] [PubMed]
  107. Clarke CS, Hunter RM, Shemilt I, Serra-Sastre V. Multi-arm cost-effectiveness analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PLOS ONE 2017;12:e0172731. https://doi.org/10.1371/journal.pone.0172731 doi: 10.1371/journal.pone.0172731. [DOI] [PMC free article] [PubMed]
  108. Cancer Research UK. Fatigue and Cancer Drugs. London: Cancer Research UK; 2017. URL: www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/side-effects/fatigue (accessed 7 September 2017).
  109. Narayanan V, Koshy C. Fatigue in cancer: a review of literature. Indian J Palliat Care 2009;15:19–25. https://doi.org/10.4103/0973-1075.53507 doi: 10.4103/0973-1075.53507. [DOI] [PMC free article] [PubMed]
  110. Murphy E, Dingwall R, Greatbatch D, Parker S, Watson P. Qualitative research methods in health technology assessment: a review of the literature. Health Technol Assess 1998;2(16). https://doi.org/10.3310/hta2160 doi: 10.3310/hta2160. [DOI] [PubMed]
  111. Rich JL, Chojenta C, Loxton D. Quality, rigour and usefulness of free-text comments collected by a large population based longitudinal study – ALSWH. PLOS ONE 2013;8:e68832. https://doi.org/10.1371/journal.pone.0068832 doi: 10.1371/journal.pone.0068832. [DOI] [PMC free article] [PubMed]
  112. York GS, Churchman R, Woodard B, Wainright C, Rau-Foster M. Free-text comments: understanding the value in family member descriptions of hospice caregiver relationships. Am J Hosp Palliat Care 2012;29:98–105. https://doi.org/10.1177/1049909111409564 doi: 10.1177/1049909111409564. [DOI] [PubMed]
  113. Corner J, Wagland R, Glaser A, Richards SM. Qualitative analysis of patients’ feedback from a PROMs survey of cancer patients in England. BMJ Open 2013;3:e002316. https://doi.org/10.1136/bmjopen-2012-002316 doi: 10.1136/bmjopen-2012-002316. [DOI] [PMC free article] [PubMed]
  114. Parsonage RK, Hiscock J, Law RJ, Neal RD. Patient perspectives on delays in diagnosis and treatment of cancer: a qualitative analysis of free-text data. Br J Gen Pract 2017;67:e49–56. https://doi.org/10.3399/bjgp16X688357 doi: 10.3399/bjgp16X688357. [DOI] [PMC free article] [PubMed]
  115. O’Cathain A, Thomas KJ. ‘Any other comments?’ Open questions on questionnaires – a bane or a bonus to research? BMC Med Res Methodol 2004;4:25. https://doi.org/10.1186/1471-2288-4-25 doi: 10.1186/1471-2288-4-25. [DOI] [PMC free article] [PubMed]
  116. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353:1734–6. https://doi.org/10.1056/NEJMe058196 doi: 10.1056/NEJMe058196. [DOI] [PubMed]
  117. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012;308:2594–604. https://doi.org/10.1001/jama.2012.87802 doi: 10.1001/jama.2012.87802. [DOI] [PubMed]
  118. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007;25:2127–32. https://doi.org/10.1200/JCO.2006.10.3523 doi: 10.1200/JCO.2006.10.3523. [DOI] [PubMed]
  119. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015;45(Pt A):139–45. https://doi.org/10.1016/j.cct.2015.09.002 doi: 10.1016/j.cct.2015.09.002. [DOI] [PMC free article] [PubMed]
  120. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015;372:134–41. https://doi.org/10.1056/NEJMoa1406281 doi: 10.1056/NEJMoa1406281. [DOI] [PMC free article] [PubMed]
  121. Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2019;37:1868–75. https://doi.org/10.1200/JCO.19.00066 doi: 10.1200/JCO.19.00066. [DOI] [PMC free article] [PubMed]
  122. Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol 2013;14:1121–8. https://doi.org/10.1016/S1470-2045(13)70384-X doi: 10.1016/S1470-2045(13)70384-X. [DOI] [PubMed]
  123. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327–33. https://doi.org/10.1093/jnci/85.16.1327 doi: 10.1093/jnci/85.16.1327. [DOI] [PubMed]
  124. Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 1976;36:2891–5. [PubMed]
  125. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010;17:421–33. https://doi.org/10.1016/j.chembiol.2010.04.012 doi: 10.1016/j.chembiol.2010.04.012. [DOI] [PMC free article] [PubMed]
  126. Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun 2013;4:1908. https://doi.org/10.1038/ncomms2921 doi: 10.1038/ncomms2921. [DOI] [PMC free article] [PubMed]
  127. Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J. Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nat Chem Biol 2015;11:472–80. https://doi.org/10.1038/nchembio.1811 doi: 10.1038/nchembio.1811. [DOI] [PubMed]
  128. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011;8:151–60. https://doi.org/10.1038/nrclinonc.2010.223 doi: 10.1038/nrclinonc.2010.223. [DOI] [PubMed]
  129. Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res 2013;19:28–33. https://doi.org/10.1158/1078-0432.CCR-11-2701 doi: 10.1158/1078-0432.CCR-11-2701. [DOI] [PubMed]
  130. Kroemer G, Senovilla L, Galluzzi L, André F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med 2015;21:1128–38. https://doi.org/10.1038/nm.3944 doi: 10.1038/nm.3944. [DOI] [PubMed]
  131. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014;20:1301–9. https://doi.org/10.1038/nm.3708 doi: 10.1038/nm.3708. [DOI] [PubMed]
  132. Parkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst 2017;109:. https://doi.org/10.1093/jnci/djw199 doi: 10.1093/jnci/djw199. [DOI] [PMC free article] [PubMed]
  133. Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol 2014;25:1536–43. https://doi.org/10.1093/annonc/mdu191 doi: 10.1093/annonc/mdu191. [DOI] [PubMed]
  134. Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018;19:40–50. https://doi.org/10.1016/S1470-2045(17)30904-X doi: 10.1016/S1470-2045(17)30904-X. [DOI] [PubMed]
  135. Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol 2017;18:52–62. https://doi.org/10.1016/S1470-2045(16)30631-3 doi: 10.1016/S1470-2045(16)30631-3. [DOI] [PMC free article] [PubMed]
  136. Dieci MV, Conte P, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, et al. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. Ann Oncol 2019;30:418–23. https://doi.org/10.1093/annonc/mdz007 doi: 10.1093/annonc/mdz007. [DOI] [PMC free article] [PubMed]
  137. Altman DG. Clinical trials: subgroup analyses in randomized trials – more rigour needed. Nat Rev Clin Oncol 2015;12:506–7. https://doi.org/10.1038/nrclinonc.2015.133 doi: 10.1038/nrclinonc.2015.133. [DOI] [PubMed]
  138. Peto R. Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care. Br J Cancer 2011;104:1057–8. https://doi.org/10.1038/bjc.2011.79 doi: 10.1038/bjc.2011.79. [DOI] [PMC free article] [PubMed]
  139. Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ 2012;344:e1553. https://doi.org/10.1136/bmj.e1553 doi: 10.1136/bmj.e1553. [DOI] [PubMed]
  140. Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users’ guide to the medical literature. JAMA 2014;311:405–11. https://doi.org/10.1001/jama.2013.285063 doi: 10.1001/jama.2013.285063. [DOI] [PubMed]
  141. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017;377:122–31. https://doi.org/10.1056/NEJMoa1703643 doi: 10.1056/NEJMoa1703643. [DOI] [PMC free article] [PubMed]
  142. Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016;17:367–77. https://doi.org/10.1016/S1470-2045(15)00551-3 doi: 10.1016/S1470-2045(15)00551-3. [DOI] [PubMed]
  143. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:1688–700. https://doi.org/10.1016/S1470-2045(17)30717-9 doi: 10.1016/S1470-2045(17)30717-9. [DOI] [PubMed]
  144. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25–32. https://doi.org/10.1016/S1470-2045(11)70336-9 doi: 10.1016/S1470-2045(11)70336-9. [DOI] [PubMed]
  145. Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016;17:791–800. https://doi.org/10.1016/S1470-2045(16)00163-7 doi: 10.1016/S1470-2045(16)00163-7. [DOI] [PubMed]
  146. Howie LJ, Scher NS, Amiri-Kordestani L, Zhang L, King-Kallimanis BL, Choudhry Y, et al. FDA approval summary: pertuzumab for adjuvant treatment of HER2-positive early breast cancer. Clin Cancer Res 2019;25:2949–55. https://doi.org/10.1158/1078-0432.CCR-18-3003 doi: 10.1158/1078-0432.CCR-18-3003. [DOI] [PubMed]
  147. National Institute for Health and Care Excellence (NICE). Pertuzumab for Adjuvant Treatment of HER2-positive Early Stage Breast Cancer. Technology appraisal guidance [TA569]. London: NICE; 2019. URL: www.nice.org.uk/guidance/ta569 (accessed 3 July 2020).
  148. National Institute for Health and Care Excellence. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab. URL: www.nice.org.uk/guidance/ta612 (accessed 15 July 2020).
  149. Esserman LJ, DeMichele A. Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change? Clin Cancer Res 2014;20:3632–6. https://doi.org/10.1158/1078-0432.CCR-13-3131 doi: 10.1158/1078-0432.CCR-13-3131. [DOI] [PubMed]
  150. European Medicines Agency. Perjeta. Amsterdam: EMA; 02/04/2013 [updated 28/06/2018]. URL: www.ema.europa.eu/en/medicines/human/EPAR/perjeta#authorisation-details-section.
  151. National Institute for Health and Care Excellence (NICE). Pertuzumab for the Neoadjuvant Treatment of HER2-positive Breast Cancer. Technology appraisal guidance [TA424]. London: NICE; 2016. URL: www.nice.org.uk/guidance/ta424 (accessed 3 July 2020).
  152. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019;380:617–28. https://doi.org/10.1056/NEJMoa1814017 doi: 10.1056/NEJMoa1814017. [DOI] [PubMed]
  153. Piccart MJ. Why your preferred targeted drugs may become unaffordable. Cancer Res 2013;73:5849–51. https://doi.org/10.1158/0008-5472.CAN-13-1486 doi: 10.1158/0008-5472.CAN-13-1486. [DOI] [PubMed]
  154. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. https://doi.org/10.3322/caac.21492 doi: 10.3322/caac.21492. [DOI] [PubMed]
  155. World Health Organization. WHO Model List of Essential Medicines [11/2015]. Geneva: WHO; 2015. URL: www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1 (accessed 3 July 2020).
  156. Daily Nation. WHO Updates List of Essential Drugs. URL: www.nation.co.ke/kenya/healthy-nation/who-updates-list-of-essential-drugs-409508
  157. Coory M, Thornton K. Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review. Breast Cancer Res Treat 2019;176:17–25. https://doi.org/10.1007/s10549-019-05227-7 doi: 10.1007/s10549-019-05227-7. [DOI] [PubMed]
  158. Curtis L, Burns A. Unit Costs of Health and Social Care 2017. Canterbury: Personal Social Services Research Unit, University of Kent; 2017.
  159. Marcheselli R, Marcheselli L, Cortesi L, Bari A, Cirilli C, Pozzi S, et al. Risk of second primary malignancy in breast cancer survivors: a nested population-based case-control study. J Breast Cancer 2015;18:378–85. https://doi.org/10.4048/jbc.2015.18.4.378 doi: 10.4048/jbc.2015.18.4.378. [DOI] [PMC free article] [PubMed]
  160. Cancer Research UK. Cancer Incidence by Age. URL: www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/age#heading-Zero (accessed 1 November 2019).
  161. National Institute for Health and Care Excellence (NICE). Ribociclib with an Aromatase Inhibitor for Previously Untreated, Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer. Technology appraisal guidance [TA496]. London: NICE; 2017. URL: www.nice.org.uk/guidance/ta496 (accessed 3 July 2020).

RESOURCES